1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Risk Factors: new trials by email Literature Review of Risk Factors trials Research Report on Risk Factors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CANVAS - CANagliflozin cardioVascular Assessment Study Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Phase 3 | Completed | Janssen Research & Development, LLC | 4330 | 2009-12-09 | 2018-12-07 |
Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1)
Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Canagliflozin (1)
Janssen Research & Development, LLC (1)
Argentina (1) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Czechia (1) · Estonia (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Israel (1) · Luxembourg (1) · Malaysia (1) · Mexico (1)
PMID 23895803, PMID 24517339, PMID 24786834, PMID 25468945, PMID 26081793, PMID 26121561, PMID 26580237, PMID 28605608, PMID 29103664, PMID 29133604, PMID 29526832, PMID 29693360, PMID 29937267, PMID 29941478, PMID 30591006, PMID 30882240, PMID 31399845, PMID 32691499, PMID 32694216, PMID 32971190, PMID 33121714, PMID 33158949, PMID 33595905, PMID 33826709, PMID 34448033, PMID 34876454, PMID 35115099, PMID 35724306, PMID 35938182, PMID 36443792, PMID 37120538, PMID 37149821, PMID 37345834, PMID 37543256, PMID 37671609, PMID 38240199, PMID 38770818, PMID 38807510, PMID 38932575, PMID 39014523, PMID 39844714, PMID 40105285, PMID 40239057, PMID 40689549, PMID 41196655, PMID 41198855, PMID 41926219
2009 (1)